[go: up one dir, main page]

MX2018005071A - Tratamiento del cancer de pulmon de celulas pequeñas con un inhibidor de parp. - Google Patents

Tratamiento del cancer de pulmon de celulas pequeñas con un inhibidor de parp.

Info

Publication number
MX2018005071A
MX2018005071A MX2018005071A MX2018005071A MX2018005071A MX 2018005071 A MX2018005071 A MX 2018005071A MX 2018005071 A MX2018005071 A MX 2018005071A MX 2018005071 A MX2018005071 A MX 2018005071A MX 2018005071 A MX2018005071 A MX 2018005071A
Authority
MX
Mexico
Prior art keywords
treatment
lung cancer
small cell
cell lung
parp inhibitor
Prior art date
Application number
MX2018005071A
Other languages
English (en)
Inventor
Feng Ying
E Post Leonard
Shen Yuqiao
Ru Yuanbin
Wang Evelyn
Yu Karen
Original Assignee
Medivation Tech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivation Tech Llc filed Critical Medivation Tech Llc
Publication of MX2018005071A publication Critical patent/MX2018005071A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

Se describen métodos para el tratamiento de un sujeto con cáncer de pulmón de células pequeñas que expresa Schlafen-11 (SLFN 11) con un inhibidor de poli(ADP-ribosa) polimerasas (PARP) o una sal farmacéuticamente aceptable del mismo. Específicamente, el método comprende la detección de SLFN 11 en una muestra de células tumorales del sujeto, y la administración al sujeto de una cantidad eficaz de un inhibidor de PARP, tal como talazoparib o la sal de tosilato de talazoparib.
MX2018005071A 2015-10-26 2016-10-26 Tratamiento del cancer de pulmon de celulas pequeñas con un inhibidor de parp. MX2018005071A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562246538P 2015-10-26 2015-10-26
PCT/US2016/058928 WO2017075091A1 (en) 2015-10-26 2016-10-26 Treatment of small cell lung cancer with a parp inhibitor

Publications (1)

Publication Number Publication Date
MX2018005071A true MX2018005071A (es) 2018-11-29

Family

ID=58631864

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005071A MX2018005071A (es) 2015-10-26 2016-10-26 Tratamiento del cancer de pulmon de celulas pequeñas con un inhibidor de parp.

Country Status (13)

Country Link
US (1) US20190054087A1 (es)
EP (1) EP3368041A4 (es)
JP (1) JP2018536700A (es)
KR (1) KR20180100546A (es)
CN (1) CN108883115A (es)
AU (1) AU2016346351A1 (es)
BR (1) BR112018008503A2 (es)
CA (1) CA3003422A1 (es)
IL (1) IL258900A (es)
MX (1) MX2018005071A (es)
RU (1) RU2018119128A (es)
SG (1) SG11201803462PA (es)
WO (1) WO2017075091A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3478286B1 (en) 2016-06-29 2024-01-03 Tesaro, Inc. Methods of treating ovarian cancer
EP3519051B1 (en) 2016-09-27 2021-09-22 Beigene, Ltd. Treatment of cancers using combination comprising parp inhibitors
TWI879716B (zh) 2017-05-09 2025-04-11 美商提薩羅有限公司 治療癌症的組合療法
MA49144A (fr) 2017-05-18 2020-03-25 Tesaro Inc Polythérapies pour le traitement du cancer
CN110891579A (zh) * 2017-06-20 2020-03-17 南坦生物组学有限责任公司 用于优化癌症治疗方案的slfn11蛋白的量化
WO2019015561A1 (en) * 2017-07-17 2019-01-24 Beigene, Ltd. TREATMENT OF CANCERS USING A COMBINATION COMPRISING INHIBITORS OF PARP, TEMOZOLOMIDE AND / OR RADIOTHERAPY
CA3076515A1 (en) 2017-09-30 2019-04-04 Tesaro, Inc. Combination therapies for treating cancer
MA50618A (fr) 2017-10-06 2020-08-12 Tesaro Inc Polyrhérapies et leurs utilisations
CA3078806A1 (en) 2017-10-13 2019-04-18 Merck Patent Gmbh Combination of a parp inhibitor and a pd-1 axis binding antagonist
TW201938165A (zh) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
KR20200105862A (ko) * 2017-12-27 2020-09-09 테사로, 인코포레이티드 암을 치료하는 방법
US20210355223A1 (en) 2018-11-05 2021-11-18 Pfizer Inc. Combinations for Treating Cancer
CA3174908A1 (en) 2020-03-09 2021-09-16 Pfizer Inc. Fusion proteins and uses thereof
KR20230107647A (ko) * 2020-11-13 2023-07-17 화이자 인코포레이티드 탈라조파립 연질 젤라틴 캡슐 투여 형태
CA3203814A1 (en) 2020-12-07 2022-06-16 Pfizer Inc. Methods of identifying a tumor that is sensitive to treatment with talazoparib and methods of treatment thereof
EP4304653A4 (en) * 2021-03-10 2024-12-18 Astrazeneca AB METHODS FOR TREATING SMALL CELL LUNG CANCER AND OTHER NEUROENDOCRINE CANCERS
BR112023018906A2 (pt) 2021-03-24 2023-10-10 Astellas Pharma Inc Combinação de talazoparib e um antiandrógeno para o tratamento de câncer de próstata metastático sensível à castração com mutação no gene ddr
WO2023131894A1 (en) 2022-01-08 2023-07-13 Pfizer Inc. Genomic loss of heterozygosity as a predictive biomarker for treatment with talazoparib and methods of treatment thereof
TWI883565B (zh) 2022-10-02 2025-05-11 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
WO2024090805A1 (ko) * 2022-10-27 2024-05-02 이원다이애그노믹스(주) 폐암 진단용 메틸화 마커 및 이의 조합
TW202425976A (zh) 2022-12-17 2024-07-01 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
WO2025210510A1 (en) 2024-04-04 2025-10-09 Pfizer Inc. Tmprss2-erg and rb1 as predictive biomarkers for treatment with a parp inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010091140A1 (en) * 2009-02-04 2010-08-12 Bipar Sciences, Inc. Treatment of lung cancer with a parp inhibitor in combination with a growth factor inhibitor
AU2011212928B2 (en) * 2010-02-03 2016-06-23 Medivation Technologies Llc Dihydropyridophthalazinone inhibitors of poly(ADP-ribose) polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency
US20130317027A1 (en) * 2010-03-01 2013-11-28 Myrexis, Inc. Compounds and therapeutic uses thereof
ES2816600T3 (es) * 2010-10-21 2021-04-05 Medivation Tech Llc Sal tosilato de (8S,9R)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1H-1,2,4-triazol-5-il)-8,9-dihidro-2H-pirido[4,3,2-de]ftalazin-3(7H)-ona cristalina
US20150044288A1 (en) * 2013-07-31 2015-02-12 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof

Also Published As

Publication number Publication date
EP3368041A4 (en) 2019-07-17
RU2018119128A3 (es) 2020-03-03
CA3003422A1 (en) 2017-05-04
WO2017075091A1 (en) 2017-05-04
RU2018119128A (ru) 2019-11-28
AU2016346351A1 (en) 2018-05-24
US20190054087A1 (en) 2019-02-21
EP3368041A1 (en) 2018-09-05
SG11201803462PA (en) 2018-05-30
JP2018536700A (ja) 2018-12-13
KR20180100546A (ko) 2018-09-11
CN108883115A (zh) 2018-11-23
BR112018008503A2 (pt) 2018-10-23
IL258900A (en) 2018-06-28

Similar Documents

Publication Publication Date Title
MX2018005071A (es) Tratamiento del cancer de pulmon de celulas pequeñas con un inhibidor de parp.
MX2017015473A (es) Tratamiento contra el cancer por manipulacion de la microflora comensal.
WO2019067666A8 (en) Therapeutic methods relating to hsp90 inhibitors
SI3640251T1 (sl) Derivati 6,7,8,9-tetrahidro-3H-pirazolo(4,3-f)izokinolina uporabni v zdravljenju raka
WO2019090347A8 (en) Adenosine pathway inhibitors for cancer treatment
EA201790398A1 (ru) Способы лечения заболевания печени
WO2016025635A3 (en) Combination therapy for treating cancer
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
EA201790913A1 (ru) Лечение заболеваний, связанных с активацией звездчатых клеток печени, с применением видов терапии, снижающих уровень аммиака
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
HK1252816A1 (zh) Tlr8激活剂治疗癌症的应用
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
MX375716B (es) Método para tratar adenocarcinoma de pulmón.
WO2016043874A3 (en) Combination therapy for treating cancer
SG11201705450SA (en) Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases
MX2017014641A (es) Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa).
WO2016160621A3 (en) Nk-92 cells in combination therapy with cancer drugs
MX2016016388A (es) Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña.
WO2014151606A3 (en) Methods of treating pancreatic cancer
HK1254954A1 (zh) Lpt-723和免疫检查点抑制剂组合物及其治疗方法
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
IL276406A (en) Osimertinib for use in the treatment of non-small cell lung cancer
PH12018501443A1 (en) Methods of administering hepcidin
DK3250711T3 (da) Fremgangsmåde og produkt til at forhindre falske positiver i fremgangsmåder anvendende ddntp'er
EP4328319A3 (en) Methods and compositions for identifying and treating patients with small cell lung cancer